Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Mar;19(3):344-56.
doi: 10.1016/j.bbmt.2012.08.011. Epub 2012 Aug 24.

Fifty years of melphalan use in hematopoietic stem cell transplantation

Ulas D Bayraktar  1 , Qaiser Bashir, Muzaffar Qazilbash, Richard E Champlin, Stefan O Ciurea
Affiliations
Review

Fifty years of melphalan use in hematopoietic stem cell transplantation

Ulas D Bayraktar et al. Biol Blood Marrow Transplant. 2013 Mar.

Abstract

Melphalan remains the most widely used agent in preparative regimens for hematopoietic stem cell transplantation (SCT). From its initial discovery more than 50 years ago, it has been gradually incorporated in the conditioning regimens for both autologous and allogeneic transplantations because of its myeloablative properties and broad antitumor effects as a DNA alkylating agent. Melphalan remains the mainstay conditioning for multiple myeloma and lymphomas, and it has been used successfully in preparative regimens of a variety of other hematological and nonhematological malignancies. The addition of newer agents to conditioning, such as bortezomib or lenalidomide for myeloma or clofarabine for myeloid malignancies, may improve antitumor effects for transplantation, whereas melphalan in combination with alemtuzumab may represent a backbone for future cellular therapy because of reliable engraftment and low toxicity profile. This review summarizes the development and the current use of this remarkable drug in hematopoietic SCT.

PubMed Disclaimer

References

    1. Bergel F, Stock JA. Cytotoxic alpha amino acids and endopeptidase. Br Emp Cancer Comp Annu. 1953;31:6–21.
    1. Sarosy G, Leyland-Jones B, Soochan P, Cheson BD. The systemic administration of intravenous melphalan. J Clin Oncol. 1988;6:1768–1782. - PubMed
    1. Singhal S, Powles R, Treleaven J, Horton C, Swansbury GJ, Mehta J. Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: Alloengraftment with potential preservation of fertility in women. Bone Marrow Transpl. 1996;18:1049–1055. - PubMed
    1. Samuels BL, Bitran JD. High-Dose Intravenous Melphalan - a Review. J Clin Oncol. 1995;13:1786–1799. - PubMed
    1. Vistica DT. Cytotoxicity as an indicator for transport mechanism: evidence that melphalan is transported by two leucine-preferring carrier systems in the L1210 murine leukemia cell. Biochimica et biophysica acta. 1979;550:309–317. - PubMed

MeSH terms